Structure via PubChem · Public domain (PubChem)
roflumilast
Sign in to saveAlso known as BY-217, BYK-20869, ROF
Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464383196
- Drug.image
- Roflumilast structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 240
- Drug.image2
- Roflumilast ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 240
- Drug.tradename
- Daxas, Daliresp, Zoryve, others
- Drug.MedlinePlus
- a611034
- Drug.DailyMedID
- Roflumilast
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, topical
- Drug.class
- PDE4 inhibitor
- Drug.ATC_prefix
- R03
- Drug.ATC_suffix
- DX07
- Drug.legal_AU
- S4
via Wikipedia infobox
Chemical data
- Formula
- C17H14Cl2F2N2O3
- Molecular weight
- 403.2 g/mol
- IUPAC name
- 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide
- SMILES
- C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
- InChIKey
- MNDBXUUTURYVHR-UHFFFAOYSA-N
- XLogP
- 4.6
- Polar surface area
- 60.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Wikidata facts
- Mass
- 402.035
- Official website
- www.daliresp.com
Show 5 more facts
- chemical formula
- C₁₇H₁₄Cl₂F₂N₂O₃
- canonical SMILES
- C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
- World Health Organisation international non-proprietary name
- roflumilast
- defined daily dose
- 0.5
- Commons category
- Roflumilast
Sources (6)
via Wikidata · CC0
~2 min read
Article
6 sectionsContents
- Medical uses
- Adverse effects
- Society and culture
- Legal status
- References
- Further reading
Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects.
It was approved for medical use in the European Union in 2010, in the United States in 2011, and in Canada in 2017. It is available as a generic medication.